Literature DB >> 16131435

Type 2N von Willebrand disease.

Claudine Mazurier1, Lysiane Hilbert.   

Abstract

Type 2N von Willebrand disease (VWD) refers to patients with a factor VIII (FVIII) deficiency caused by a markedly decreased affinity of von Willebrand factor (VWF) for FVIII. It is inherited as an autosomal recessive trait but is clinically similar to mild hemophilia. The differential biologic diagnosis, which is of major importance for providing relevant genetic counseling and optimal treatment, is based on the measurement of plasma VWF capacity to bind FVIII. Molecular biology techniques have allowed the identification of 20 missense mutations in the VWF gene that cause type 2N VWD. All of them induce changes in amino acid residues located in the N-terminal part of mature VWF, which contains the FVIII binding site. Their identification may provide a genetic diagnosis. Theoretically, patients with type 2N VWD should be treated with products containing VWF that is able to stabilize their endogenous normal FVIII.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16131435

Source DB:  PubMed          Journal:  Curr Hematol Rep        ISSN: 1540-3408


  4 in total

1.  Translational medicine advances in von Willebrand disease.

Authors:  D Lillicrap
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

Review 2.  von Willebrand disease: clinical and laboratory lessons learned from the large von Willebrand disease studies.

Authors:  Paula D James; David Lillicrap
Journal:  Am J Hematol       Date:  2012-03-03       Impact factor: 10.047

Review 3.  von Willebrand disease.

Authors:  Paula D James; Anne C Goodeve
Journal:  Genet Med       Date:  2011-05       Impact factor: 8.822

4.  Association between Genetic Polymorphism and Risk of von Willebrand Disease in Pakistan.

Authors:  Najma Arshad; Syed Kashif Nawaz; Riffat Iqbal; Muhammad Arshad; Farhana Musheer; Amber Naz; Iqra Mushtaq; Sara Jaleel
Journal:  Biomed Res Int       Date:  2017-12-20       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.